TABLE 1

Baseline patient characteristics

VariableValue for patients who:P value
Did not meet RIFLE criteria (n = 63)Met RIFLE criteria (n = 40)
Age (yr) [median (IQR)]50 (42–61)44 (34–57)0.66
Sex (male) [no. (%)]32 (50.8)19 (48.8)0.84
Hematological disease [no. (%)]
    Acute myelogenous leukemia/myelodysplastic syndrome40 (63.5)22 (55.0)0.07
    Acute lymphocytic leukemia8 (12.7)9 (22.5)0.13
    Lymphoma7 (11.1)9 (22.5)0.16
    Chronic myeloproliferative syndrome4 (6.3)1 (2.5)0.65
    Chronic lymphocytic leukemia1 (1.6)1 (2.5)0.99
    Myeloma3 (4.8)1 (2.5)1.00
    Aplastic anemia0 (0)1 (2.5)0.39
Disease status [no. (%)]
    Complete remission21 (33.3)18 (45.0)0.30
    At initial diagnosis12 (19.0)7 (17.5)0.99
    Relapse/progression30 (47.6)15 (37.5)0.21
Treatment [no. (%)]
    Induction chemotherapy23 (36.5)11 (27.5)0.39
    Consolidation chemotherapy8 (12.7)1 (2.5)0.15
    Autologous HSCT5 (7.9)1 (2.2)0.40
    Allogeneic HSCT18 (28.6)24 (47.5)0.06
    No chemotherapy8 (12.7)8 (20.0)0.41
    Experimental (targeted) therapy1 (1.6)0 (0)0.99
Neutropenia [no. (%)]59 (93.6)41 (91.9)0.40
Corticosteroids [no. (%)]16 (25.4)17 (42.5)0.09
Charlson comorbidity index [median (IQR)]4 (2–5)4 (2–5)0.97
Diabetes [no. (%)]7 (11.1)5 (12.5)0.99
Preexisting renal disease [no. (%)]1 (1.6)1 (2.5)0.99
Hepatic disease [no. (%)]2 (3.2)1 (2.5)0.99
Required ICU care [no. (%)]7 (11.1)2 (5.0)0.31
Prophylaxis [no. (%)]
    Nystatin (nonabsorbable)7 (11.1)2 (5.0)0.47
    Itraconazole7 (11.1)2 (5.0)0.47
    Fluconazole27 (42.9)25 (62.5)0.07
    Posaconazole8 (12.7)3 (7.5)0.52
    Voriconazole2 (3.2)1 (2.5)0.99
    L-AMB7 (11.1)3 (7.5)0.73
    Caspofungin0 (0)3 (7.5)0.06
    None5 (7.9)1 (2.5)0.40
Indications [no. (%)]
    Possible fungal infection22 (34.9)19 (47.5)0.22
    Probable fungal infection23 (36.5)11 (27.5)0.39
    Proven fungal infection8 (12.7)4 (10.0)0.76
Preemptive [no. (%)]8 (12.7)4 (10.0)0.76
Empirical therapy [no. (%)]2 (3.2)2 (5.0)0.64
IFI culture documented [no. (%)]
    Aspergillus spp.10 (15.9)3 (7.5)0.34
    Candida spp.2 (3.2)1 (2.5)0.66
    Blastoschizomyces spp.0 (0)1 (2.5)0.21
    No culture documentation51 (81.0)35 (87.5)0.43
Outcome [no. (%)]
    Discharged without antifungal17 (27.0)13 (32.5)0.66
    Discharged with antifungal29 (46.0)15 (37.5)0.41
    Died with invasive fungal infection11 (17.5)9 (22.5)0.53
    Death from other cause1 (1.6)1 (2.5)0.99
No. of hospitalization days [median (IQR)]42 (33.5–64.5)43.5 (26–61)0.61